References
- ALSUntangled online. Available at https://www.alsuntangled.com/future-reviews/. Accessed December 8, 2021.
- Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40:235–43.
- Salvi PS, Cowles RA. Butyrate and the intestinal epithelium: modulation of proliferation and inflammation in homeostasis and disease. Cells 2021;10:1775.
- Rizzetto L, Fava F, Tuohy KM, Selmi C. Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex. J Autoimmun. 2018;92:12–34.
- Venegas D, De la Fuente M, Landskron G, Gonzalez M, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol 2019;10:277.
- Rutsch A, Kantsjo J, Ronchi F. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front Immunol. 2020;11:604179.
- Erber AC, Cetin H, Berry D, Schernhammer ES. The role of gut microbiota, butyrate and proton pump inhibitors in amyotrophic lateral sclerosis: a systematic review. Int J Neurosci. 2020;130:727–35.
- Bourassa M, Alim I, Bultman S, Ratan R. Butyrate, neuroepigenetics and the gut microbiome: can a high fiber diet improve brain health? Neurosci Lett. 2016;625:56–63.
- Silva Y, Bernardi A, Frozza R. The role of short chain fatty acids from gut microbiota in gut-brain communication. Front Endocrin 2020;11:25.
- ALSTreatment (online). Available at https://alstreatment.com/use-butyrate-delaying-als-symptoms-increasing-life-span-mouse-models/. Accessed November 4, 2021.
- Pituch A, Walkowiak J, Banaszkiewicz A. Butyric acid in functional constipation. Prz Gastroenterol. 2013;8:295–8.
- Wikipedia (online). Available at https://en.wikipedia.org/wiki/Sodium_butyrate. Accessed November 26, 2021.
- Jellbauer S, Lopez A, Behnsen J, Gao N, Nguyen T, Murphy C, et al. Beneficial effects of sodium phenylbutyrate administration during infection with Salmonella enterica serovar typhimurium. Infect Immun. 2016;84:2639–52.
- Cudkowicz M, Andres P, Macdonald S, Bedlack R, Choudry R, Brown R, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10:99–106.
- Sealy L. The effect of sodium phenylbutyrate on histone modifications. Cell 1978;14:115–21.
- Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978;14:105–13.
- Stilling R, de Wouw M, Clarke G, Stanton C, Dinan T, Cryan J. The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis. Neurochem Int. 2016;99:110–32.
- McCauley M, Baloh R. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715–30.
- Zimmerman M, Singh N, Martin P, Thangaraju M, Ganapathy V, Waller J, et al. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1405–G1415.
- Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Busetti A, et al. Microbial short chair fatty acids modulate CD8+ T cell responses and improve adaptive immunotherapy for cancer. Nature Comm 2021;12:4077.
- Giovannelli I, Heath P, Shaw P, Kirby J. The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therapeutic potential. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:435–44.
- Zhang L, Liu C, Jiang Q, Yin Y. Butyrate in energy metabolism: there is still more to learn. Trends Endocrinol Metab. 2021;32:159–69.
- Wenzel T, Gates E, Ranger A, Klegeris A. Short-chain fatty acids (SCFAs) alone or in combination regulate select immune functions of microglia-like cells. Mol Cell Neurosci. 2020;105:103493.
- Chen PS, Wang C-C, Bortner CD, Peng G-S, Wu X, Pang H, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscoence 2007;149:203–12.
- Huuskonen J, Suuronen T, Nuutinen T, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br J Pharmacol. 2004;141:874–80.
- Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol. 2018;135:489–509.
- Guillot S, Bolborea M, Dupuis L. Dysregulation of energy homeostasis in amyotrophic lateral sclerosis. Curr Opinion Neurol 2021;34:773–780.
- Clark A, Mach N. The crosstalk between the gut microbiota and mitochondria during exercise. Front Physiol. 2017;8:319.
- Wu S, Yi J, Zhang YG, Zhou J, Sun J. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep. 2015;3:e12356.
- Zhang YG, Wu S, Yi J, Xia Y, Jin D, Zhou J, et al. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther. 2017;39:322–36.
- Zhang Y, Ogbu D, Garrett S, Xia Y, Sun J. Aberrant enteric neuromuscular system and dysbiosis in amyotrophic lateral sclerosis. Gut Microbes. 2021;13:1996848.
- Ryu H, Smith K, Camelo S, Carreras I, Lee J, Iglesias A, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93:1087–98.
- PatientsLikeMe (online). Available at https://www.patientslikeme.com/treatment_evaluations/browse?brand=false&condition_id=9&id=30089. Accessed December 3, 2021.
- ALS Reversals (online). Available at http://www.alsreversals.com. Accessed December 3, 2021.
- Harrison D, Mehta P, Van Es M, Stommel E, Drory V, Nefussy B, et al. “ALS reversals": demographics, disease characteristics, treatments, and co-morbidities:”. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:495–9.
- Paganoni S, Macklin E, Hendrix S, Berry J, Elliott M, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–30.
- Paganoni S, Hendrix S, Dickson S, Knowlton N, Macklin E, Berry J, et al. Long-term survival of participants in the Centaur trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63:31–9.
- Elia AE, Lalli S, Monsurrò MR, Sagnelli A, Taiello AC, Reggiori B, et al. Tauroursodeoxycholic acid in the treatment of patietns with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23:45–52.
- Fang X, Wang X, Yang S, Meng F, Wang X, Wei H, et al. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing. Front Microbiol. 2016;7:1479.
- Nicholson K, Bjornevik K, Abu-Ali G, Chan J, Cortese M, Dedi B, et al. The human gut microbiota in people with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:186–94.
- Hertzberg VS, Singh H, Fournier CN, Moustafa A, Polak M, Kuelbs CA, et al. Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls. Amyotroph Lateral Scler Frontotemporal Degener 2021;2021:1–9.
- Niccolai E, Di Pilato V, Nannini G, Baldi S, Russo E, Zucchi E, et al. The gut microbiota-immunity axis in ALS: a role in deciphering disease heterogeneity? Biomedicines 2021;9:753.
- Ngo ST, Restuadi R, McCrae AF, Van Eijk RP, Garton F, Henderson RD, et al. Progression and survival of patients with motor neuron disease relative to their fecal microbiota. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:549–62.
- NaPB package insert (online). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020572s016,020573s015lbl.pdf. Accessed December 6, 2021.
- Sabatino AD, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, et al. Oral butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol Ther. 2005;22:789–94.
- Amazon (online). Available at https://www.amazon.com/Gut-Health-Supplement-100-Caps/dp/B0058A9SF0?th=1. Accessed December 6, 2021.
- Drugs (online). Available at https://www.drugs.com/price-guide/sodium-phenylbutyrate. Accessed December 6, 2021.